Clinical Trials Logo

Clinical Trial Summary

The present clinical phase I study designed to examine the safety, reactogenicity and immunogenicity of the medicinal product - Vaccine vector against influenza A - in healthy volunteers after a single dose in the three groups with dose escalation.


Clinical Trial Description

According to the results of the screening of volunteers who signed the informed consent Form, a sequential set of three groups of volunteers with different doses of the drug, the total number of volunteers who received the drug will be at least 36 people.

Given the fact that the drug is investigated for the first time with the participation of the people, will initially be admitted to hospital on 5 volunteers who will receive the investigational drug in the 1 dose The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 10*10 VP/dose). If the safety of the drug is confirmed by the results of observation on the 7th day of the study, the study will continue with the participation of 7 more volunteers in this dosing group.

Further, according to a similar scheme (each time after an interim safety assessment on day 7), the study will include volunteers receiving the drug at a dose of 0.5 ml (Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose), particles/dose and 0.5 ml, -The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03651544
Study type Interventional
Source Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Contact
Status Completed
Phase Phase 1
Start date October 15, 2018
Completion date March 14, 2019

See also
  Status Clinical Trial Phase
Completed NCT03999554 - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines Phase 1
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT02487173 - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B N/A
Completed NCT01701752 - Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults Phase 1
Enrolling by invitation NCT03207152 - Biomarkers Predicting Infectivity in an Experimental Human Influenza Model Phase 1
Terminated NCT05567783 - A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A Phase 2
Not yet recruiting NCT00987012 - The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients N/A
Not yet recruiting NCT05928507 - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed NCT02623322 - A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults Phase 2
Completed NCT03196661 - Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population Phase 1
Recruiting NCT06160531 - Influenza Viral Challenge Study of CC-42344 in Healthy Participants Phase 2
Recruiting NCT06191393 - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings N/A
Completed NCT06127108 - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel N/A
Completed NCT05163730 - Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel N/A
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT04896853 - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® Phase 1
Not yet recruiting NCT05787444 - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
Completed NCT05354115 - Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel. N/A
Completed NCT02014870 - Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers Phase 1
Completed NCT05897515 - LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia N/A